MFSD8 and juvenile neuronal ceroid lipofuscinosis: Milasen, a patient-specific ASO with PS-backbone and 2′-O-MOE modifications, was administered intrathecally in a patient with a pathogenic mutation in CLN7 causing Batten’s disease.